Please note that indications and formulations may vary from country to country. Please refer to the respective local product information or Summary of Product Characteristics (SmPC).
|Active ingredient / Technology||Brand name, examples||Indication range,
EU as example1
|Capsaicin||Qutenza®||Treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for the treatment of pain.|
|Fixed-dose combination of Esomeprazole and Naproxen||Vimovo®||In adults for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, in patients who are at risk for developing non-steroidal anti-inflammatory drug (NSAID)-associated gastric and/or duodenal ulcers and where treatment with lower doses of naproxen or of other NSAIDs is not considered sufficient.|
|Lidocaine||Versatis®||Symptomatic relief of neuropathic pain associated with previous herpes zoster infection (postherpetic neuralgia, PHN) in adults.|
|Zolmitriptan||Zomig® AscoTop®||Oral formulations:
In adults aged 18 years and older for acute treatment of migraine headache with or without aura.
In adults and adolescents aged 12 years and older for the acute treatment of migraine headache with or without aura, and in adults for the treatment of cluster headache
|Esomeprazole||Nexium®||20mg; 40mg gastro-resistant tablets:
Indicated in adolescents from the age of 12 years and in adults for:
Gastroesophageal reflux disease (GERD)
- treatment of erosive reflux esophagitis
- long-term management of patients with healed esophagitis to prevent relapse
- symptomatic treatment of GERD
Indicated in adults for:
In combination with appropriate antibacterial therapeutic regimens for the eradication of Helicobacter pylori and:
- healing of Helicobacter pylori associated duodenal ulcer and
- prevention of relapse of peptic ulcers in patients with Helicobacter pylori-associated ulcers
Patients requiring continued NSAID therapy:
- healing of gastric ulcers associated with NSAID therapy
- prevention of gastric and duodenal ulcers associated with NSAID therapy, in patients at risk
Prolonged treatment after intravenous-induced prevention of rebleeding of peptic ulcers. Treatment of Zollinger Ellison Syndrome.
Indicated in adolescents from the age of 12 years:
In combination with antibiotics in treatment of duodenal ulcer caused by Helicobacter pylori. Nexium™ is also available in other dosage forms with slightly varying indications.2
|Rosuvastatin||Crestor®||Treatment of hypercholesterolaemia
Adults, adolescents, and children aged 6 years or older with primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate.
Adults, adolescents and children aged 6 years or older with homozygous familial
hypercholesterolaemia as an adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate.
Prevention of cardiovascular events
Prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular event, as an adjunct to correction of other risk factors.
|Testosterone undecanoate||Nebido®||Treatment of male hypogonadism, when testosterone deficiency has been confirmed by clinical features and biochemical tests.|
1 Status: Status: April 2022. Please note that indications and formulations may vary from country to country. Please refer to the respective local product information or Summary of Product Characteristics (SmPC)
2 See SmPC for ‘Nexium™ 10 mg gastro-resistant granules for oral suspension, sachet’ and for ‘Nexium™ 40 mg Powder for solution for injection/infusion’